BidaskClub cut shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research note released on Wednesday.

Several other equities analysts have also recently commented on LIVN. ValuEngine cut shares of LivaNova from a buy rating to a hold rating in a research report on Wednesday, December 20th. Zacks Investment Research lowered shares of LivaNova from a hold rating to a strong sell rating in a research note on Thursday, January 25th. BTIG Research reaffirmed a hold rating on shares of LivaNova in a research note on Tuesday, November 7th. Needham & Company LLC increased their target price on shares of LivaNova from $93.00 to $97.00 and gave the stock a buy rating in a research note on Tuesday, December 5th. Finally, Jefferies Group increased their target price on shares of LivaNova from $80.00 to $91.00 and gave the stock a buy rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. LivaNova currently has a consensus rating of Hold and an average price target of $79.71.

LivaNova (NASDAQ LIVN) traded up $1.59 during trading hours on Wednesday, reaching $83.35. The company had a trading volume of 293,600 shares, compared to its average volume of 369,503. LivaNova has a one year low of $46.34 and a one year high of $88.56. The stock has a market cap of $3,941.78, a price-to-earnings ratio of 23.56, a PEG ratio of 2.43 and a beta of 0.83. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04.

In other news, Director Hugh M. Morrison sold 1,830 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $80.80, for a total transaction of $80,800.00. The disclosure for this sale can be found here. Insiders have sold 5,830 shares of company stock valued at $495,530 in the last quarter. Company insiders own 0.28% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in shares of LivaNova by 9.8% in the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after acquiring an additional 153 shares during the period. Cerebellum GP LLC purchased a new stake in LivaNova in the fourth quarter valued at approximately $128,000. QS Investors LLC raised its stake in LivaNova by 27,255.6% in the fourth quarter. QS Investors LLC now owns 2,462 shares of the company’s stock valued at $197,000 after purchasing an additional 2,453 shares in the last quarter. Pillar Pacific Capital Management LLC purchased a new stake in LivaNova in the fourth quarter valued at approximately $208,000. Finally, Shelton Capital Management purchased a new stake in LivaNova in the third quarter valued at approximately $209,000. Institutional investors own 88.53% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/15/livanova-livn-rating-lowered-to-hold-at-bidaskclub.html.

About LivaNova

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.